Evidence map›Paper›PMID 34155357›Full record

ArticleBone marrow transplantation2021

Comparison of fludarabine, a myeloablative dose of busulfan, and melphalan vs conventional myeloablative conditioning regimen in patients with relapse and refractory acute myeloid leukemia in non-remission status.

Yoshimitsu Shimomura, Masahiko Hara, Shigeki Hirabayashi, Tadakazu Kondo, Shohei Mizuno, Naoyuki Uchida, Junichi Mukae, Toshiro Kawakita, Takahiro Fukuda, Yoshinobu Kanda and 10 more

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. The Bone Marrow Microenvironment Mechanisms in Acute Myeloid Leukemia.Frontiers in cell and developmental biology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 17 institutions in 1 country.

Yoshimitsu ShimomuraDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan. shimomura_0119@yahoo.co.jp.ORCID http://orcid.org/0000-0003-1018-9508
Masahiko HaraCenter for Community-based Healthcare Research and Education, Shimane University, Shimane, Japan.
Shigeki HirabayashiDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Tadakazu KondoDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0002-8959-6271
Shohei MizunoDivision of Hematology, Department of Internal Medicine, Aichi Medical University, Nagakute, Japan.ORCID http://orcid.org/0000-0002-4405-8808
Naoyuki UchidaDepartment of hematology, Toranomon Hospital, Tokyo, Japan.ORCID http://orcid.org/0000-0001-5952-5926
Junichi MukaeHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Toshiro KawakitaDepartment of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan.
Takahiro FukudaDepartment of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Yoshinobu KandaDivision of Hematology, Saitama Medical Center Jichi Medical University, Saitama, Japan.ORCID http://orcid.org/0000-0002-4866-9307
Shuichi OtaDepartment of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan.ORCID http://orcid.org/0000-0002-3631-244X
Yukiyasu OzawaDepartment of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
Tetsuya EtoDepartment of Hematology, Hamanomachi Hospital, Fukuoka, Japan.
Yumiko MaruyamaDepartment of Hematology, University of Tsukuba Hospital, Tsukuba, Japan.
Masatsugu TanakaDepartment of Hematology, Kanagawa Cancer Center, Kanagawa, Japan.
Nobuaki NakanoDepartment of Hematology, Imamura General Hospital, Kagoshima, Japan.ORCID http://orcid.org/0000-0001-9826-7616
Takafumi KimuraPreparation Department, Japanese Red Cross Kinki Block Blood Center, Osaka, Japan.
Tatsuo IchinoheDepartment of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.ORCID http://orcid.org/0000-0002-0393-4066
Yoshiko AtsutaJapanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan.ORCID http://orcid.org/0000-0003-4404-2870
Masamitsu YanadaDepartment of Hematology and Cell Therapy, Aichi Cancer Center, Aichi, Japan.ORCID http://orcid.org/0000-0003-1602-9775
Kyoto University · JPAichi Cancer Center · JPAichi Medical University · JPHamanomachi Hospital · JPHiroshima University · JPImamura Hospital · JPJapanese Red Cross Society, Japan · JPJichi Medical University · JPKanagawa Prefectural Hospital Organization · JPKobe City Medical Center General Hospital · JPKumamoto Medical Center · JPSapporo Hokuyu Hospital · JPShimane University · JPThe Japanese Data Center for Hematopoietic Cell Transplantation · JPTokyo Metropolitan Komagome Hospital · JPToranomon Hospital · JPUniversity of Tsukuba Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteBusulfanHumansMelphalanRecurrenceRetrospective StudiesTransplantation ConditioningVidarabineBusulfanfludarabineMelphalanVidarabine

Identifiers

PMID34155357
OpenAlexW3173157367

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.